TRCT
RARX

Tower Research Capital (TRC)’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Tower Research Capital (TRC)’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-121
Closed -$6K – 5191
2020
Q1 		$6K Sell
121
-475
-80% -$22.1K ﹤0.01% 2271
2019
Q4 		$28K Sell
596
-39
-6% -$1.72K ﹤0.01% 1725
2019
Q3 		$15K Buy
+635
New +$18.8K ﹤0.01% 2703
2019
Q1 		– Sell
-2,397
Closed -$44K – 4621
2018
Q4 		$44K Buy
+2,397
New +$37.6K ﹤0.01% 1374
2018
Q3 		– Sell
-3,690
Closed -$37K – 4496
2018
Q2 		$37K Buy
3,690
+2,451
+198% +$16.9K ﹤0.01% 2049
2018
Q1 		$7K Sell
1,239
-474
-28% -$3.39K ﹤0.01% 2630
2017
Q4 		$15K Sell
1,713
-2,698
-61% -$33.2K ﹤0.01% 2295
2017
Q3 		$65K Buy
4,411
+3,951
+859% +$59.7K 0.01% 1751
2017
Q2 		$9K Buy
460
+360
+360% +$8.12K ﹤0.01% 1689
2017
Q1 		$2K Buy
100
+32
+47% +$612 ﹤0.01% 2717
2016
Q4 		$1K Buy
+68
New +$924 ﹤0.01% 3711

Other funds holding RARX

Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Tower Research Capital (TRC)'s RARX Position: Q2 2020 in Review

Tower Research Capital (TRC) sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 121 shares — an estimated $6K sold.

Tower Research Capital (TRC) first reported a position in RARX in Q4 2016 and held it in 11 quarters. The position peaked at $65K in Q3 2017. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • Tower Research Capital (TRC) reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 121 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $6K.
  • Tower Research Capital (TRC) first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 11 quarters.
  • Tower Research Capital (TRC)'s Ra Pharmaceuticals, Inc. Common Stock position peaked at $65K in Q3 2017.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2020, filed 13 Aug 2020.